Dear colleagues, dear members of the European healthtech community, on the 13th of March 2026, the European Technology Platform on Nanomedicine (ETPN) organised a new edition of its Flash Brokerage format to help the community accelerate consortium building around the most urgent Horizon Europe Health 2026 opportunities, IHI Call 12, selected EIC calls, and a few adjacent opportunities worth keeping on the radar.
The format remained simple and focused: short interventions, no generic institutional showcase, no slides, no fluff. Participants were invited either to present a concrete consortium gap or to offer a concrete expertise, and to leave a visible trace on the shared board so that useful contacts could still be found after the Zoom session.
This page is the practical follow-up of that session. It is intended both for participants who want to reconnect quickly after the event and for readers who were not present but want a clear view of where proposal-building momentum and relevant expertise emerged across the brokerage.
At a glance
Browse the pitches visually: Explore the public Miro board used during and immediately after the event to revisit the original live contribution structure and participant inputs.
⚠️ The board is shared as a public follow-up resource. The visible contributions were intentionally shared during the event for networking purposes. Please use the information and contact details responsibly and with professional discretion.
Where momentum was strongest and how ETPN members stood out
The clearest activity during the brokerage emerged around a small number of calls, with ETPN members playing a visible role both as potential coordinators and as highly relevant partners.
- TOOL-03 — one of the strongest areas of the session, combining a clear coordinator signal with a dense ecosystem of NAM, organoid, biosensing and EV-related expertise, including strong ETPN member participation.
- TOOL-05 — a convincing follow-on proposal nucleus in regenerative medicine, supported by complementary nanomedicine and delivery expertise from the network.
- DISEASE-03 and DISEASE-04 — strong partner pools, especially around biomarkers, EVs, biosensing, vaccines, RNA-LNPs and scale up, with particularly high visibility of ETPN members in DISEASE-04.
- EIC Pathfinder Open — one of the most dynamic non-Health segments of the session, with bold proposal directions and strong ETPN member visibility.
- EIC Pathfinder Challenges — a concrete Healthy Ageing coordination signal, with Inside Therapeutics helping to frame a credible challenge-oriented direction and partner needs.
Taken together, these signals highlight one of ETPN’s core strengths: connecting translational, industrial, clinical and regulatory expertise in ways that help turn fragmented capabilities into credible proposal-building momentum.
Quick navigation
- Emerging project signals from the session
- HORIZON-HLTH-2026-01-DISEASE-03
- HORIZON-HLTH-2026-01-DISEASE-04
- HORIZON-HLTH-2026-01-DISEASE-15
- HORIZON-HLTH-2026-01-TOOL-03
- HORIZON-HLTH-2026-01-TOOL-05
- HORIZON-HLTH-2026-01-TOOL-07
- HORIZON-HLTH-2026-01-IND-03
- HORIZON-HLTH-2026-04-CARE-04
- Cluster 4 radar calls
- IHI Call 12
- Mission Cancer 2026
- EIC Pathfinder Open 2026
- EIC Transition 2026
- EIC Pathfinder Challenges 2026
Browse the pitches visually: Explore the public Miro board used during and immediately after the event to revisit the original live contribution structure and participant inputs.
⚠️ The board is shared as a public follow-up resource. All visible contributions were shared during the event with the understanding that they could remain visible and be used for direct networking follow-up. Please handle the information and contact details with care and professional discretion.
Emerging project signals from the session
Below are the strongest “this could become a proposal” signals that emerged live. Some are already fairly concrete, others still need shaping, but all deserve visibility because they generated real momentum during the session.
| Call | Lead / project signal | What emerged |
|---|---|---|
| Coordinator signal TOOL-03 | University of Naples Federico II – Enza Torino enza.torino@unina.it ETPN member* | Validation Human Tumor Immune Organoids for Glioblastoma and Immunotherapy by EVs A concrete project nucleus around patient-derived tumour immune organoids, EV loading with DNA/RNA, immunotherapy validation, profiling and data analysis. |
| Coordinator signal EIC Pathfinder Open | Project BONES Valentina Cauda / Luisa De Cola valentina.cauda@polito.it luisa.decola@unimi.it ETPN member* | Bone-disease consortium idea combining EV-mimicking nanoparticles, bone-targeting chemistry, clinical bone expertise and GMP nanoparticle manufacturing; explicitly looking for AI support for targeting-peptide design. |
| Coordinator signal EIC Pathfinder Open | University Medical Center Utrecht – Zhiyong Lei zlei@umcutrecht.nl ETPN member* | Engineered EV/AAV strategies to tackle blood-brain barrier limitations in brain / neurodegeneration-related diseases, with explicit need for clinicians, disease models and upscale production support. |
| Coordinator signal EIC Pathfinder Challenges | Inside Therapeutics + Microfluidic Innovation Centers audrey.nsamela@insidetx.com ETPN member* | Healthy Ageing challenge concept around senescence / inflammaging modulation and RNA-LNP delivery, already framed with clear opportunity zones and specific needs. |
| Coordinator signal TOOL-05 | University of Salerno – Giovanna Della Porta gdellaporta@unisa.it | P4FIT Next – Advancing Perspectives for Future Innovation in Tendon A credible follow-on concept leveraging a completed EU-funded initiative in tendon regeneration, inflammation management and rehabilitation. |
| Potential lead TOOL-07 | Foundation Gene Therapy and RNA Therapeutics – Fabiana Quaglia quaglia@unina.it | A plausible network-of-CoEs lead direction in RNA therapeutics and gene therapy, promising but less mature than the stronger coordinator-style signals above. |
1) HORIZON-HLTH-2026-01-DISEASE-03 — Prevention, diagnosis, and management of post-infection long-term conditions
This call did not produce a clear coordinator signal during the session, but it generated one of the richest open pools of enabling expertise. The strongest themes were extracellular vesicles, liquid biopsy, biosensing, biomarker detection, microfluidics and translational formulation know-how.
| Affiliation | Open collaboration offer |
|---|---|
| University of Naples Federico II – Fabiana Quaglia quaglia@unina.it ETPN member* | HTFS, microfluidic formulation, DoE/QbD, GMP-oriented scale-up and tech transfer for RNA and nanoparticle-based delivery systems. |
| GENYO / University of Granada – Teresa Valero tvalero@go.ugr.es ETPN member* | Nanotech assay to isolate EVs from antigen-memory T cells; multiplex immune-memory detection at hospital level via flow cytometry / CyTOF-compatible approaches. |
| INESC MN – Ricardo Cabeça ricardo.cabeca@inesc-mn.pt ETPN member* | Advanced biosensing platforms combining microfluidics, biosensors and ASICs; photodetectors, magnetic sensors and MEMS for biomarker detection and monitoring. |
| University Medical Center Utrecht – Zhiyong Lei zei@umcutrecht.nl ETPN member* | Engineered EVs, LNPs/liposomes, mRNA production, microfluidics, LNP manufacturing and validation, patient-derived EV engineering and binder design. |
| CIDETEC – Diego Cortizo dcortizo@cidetec.es ETPN member* | 3D cell models and broader materials / scale-up capabilities relevant to biomarker enrichment, validation and translational development. |
| EVGenomics ApS – Yan Yan yan@evgenomics.com | EV isolation, EV-RNA sequencing, data integration, biomarker panels, assay translation and single-cell RNA-seq support for liquid biopsy and patient stratification. |
| CNR Nanoscience Institute, Pisa – Marco Cecchini marco-cecchini@cnr.it | Lab-on-a-chip biosensors for diagnostics and biomarker monitoring in biological fluids; SAW/BAW devices, MIP-based functionalization and particle manipulation. |
| Nano4Med Group – University of Porto mcsp@fe.up.pt | BBB-crossing nano drug delivery, lipid/polymeric/metallic nanoparticles, biosensors and full production / characterization infrastructure. |
| University of Urbino – Mattia Tiboni mattia.tiboni@uniurb.it | Custom 3D-printed microfluidics for nanomedicine synthesis with DoE-driven optimization of size, composition and functionalization. |
| Brenta pama@brenta.net | Delivery platform with relevance for chronic infection and biofilm-associated contexts where local retention and penetration are major issues. |
2) HORIZON-HLTH-2026-01-DISEASE-04 — Development of novel vaccines for viral pathogens with epidemic potential
This was one of the clearest community-fit calls of the session. It did not produce a visible coordinator, but the density of useful partner offers was high enough to make this section immediately actionable.
| Affiliation | Open collaboration offer |
|---|---|
| University of Santiago de Compostela – Maria José Alonso Lab mariaj.alonso@usc.es ETPN member* | Nanocarriers for mRNA and peptide vaccines, antigen delivery and immune activation for next-generation vaccine strategies. |
| CiMUS / USC – Marcos García marcos.garcia@usc.es ETPN member* | Polyphosphazene-based nanoadjuvants and injectable/implantable gels capable of generating VLP-like activity in situ. |
| Inside Therapeutics audrey.nsamela@insidetx.com ETPN member* | NanoPulse microfluidic platform for reproducible RNA-LNP production, formulation optimisation and manufacturing readiness from bench to GMP. |
| University of Naples Federico II – Fabiana Quaglia quaglia@unina.it ETPN member* | High-throughput formulation screening, microfluidic formulation, DoE/QbD and GMP-oriented scale-up for RNA/nanoparticle vaccine systems. |
| UNIMORE – Giovanni Tosi gtosi@unimore.it ETPN member* | LNP fabrication with GLP-level microfluidics, RNA and small-molecule delivery, tissue targeting and scalable smart manufacturing logic. |
| University of Pavia mariacristina.bonferoni@unipv.it milena.sorrenti@unipv.it sara.perteghella@unipv.it ETPN member* | Nanoformulations for nasal vaccines, multiple production techniques, DoE optimisation and in vitro safety/efficacy evaluation. |
| CIDETEC – Diego Cortizo dcortizo@cidetec.es ETPN member* | Pilot production, GMP-like conditions, polymeric/lipid systems, hydrogels and full physicochemical characterisation for vaccine manufacturing. |
| UMC Utrecht – Zhiyong Lei zlei@umcutrecht.nl ETPN member* | Engineered EVs, LNP/liposome approaches, mRNA production, microfluidics and vector engineering for vaccine or immunotherapy applications. |
| Postnova – Florian Meier florian.meier@postnova.com ETPN member* | Advanced characterization of LNPs, viruses, EVs and related systems, including stability in complex media. |
| Brenta pama@brenta.net | Mesoporous particles enabling ordered presentation of peptide antigens, with potential to enhance vaccine immunogenicity. |
3) HORIZON-HLTH-2026-01-TOOL-03 — Integrating New Approach Methodologies (NAMs)
This call deserves special attention. It combined a real coordinator signal with a broad ecosystem of relevant partners across organoids, tumour-on-chip models, human-relevant testing systems, biosensing, EV engineering, microfluidics, omics and validation.
One of the most active areas of the live board: TOOL-03 generated strong discussion around NAMs, organoids, biosensing, EVs, and consortium building.
Emerging project signal
| Lead | Project signal |
|---|---|
| University of Naples Federico II – Enza Torino enza.torino@unina.it ETPN member* | Validation Human Tumor Immune Organoids for Glioblastoma and Immunotherapy by EVs Human tumour immune organoids from patient-derived cells; EV isolation/loading with DNA and RNA; validation of organoids; cell engineering; in vivo immunotherapy; profiling and data analysis. Looking for: clinicians, SMEs, patient profiling, regulatory contacts, manufacturing platform, physico-chemical validation, bioprinting, immunomodulation and quantitative biology. |
Selected open collaboration pool around TOOL-03
| Affiliation | Offer |
|---|---|
| CiMUS / USC – Marcos García marcos.garcia@usc.es ETPN member* | TLR4 nanoparticle platform tested in vitro/in vivo for glioblastoma with immunomodulatory effects, plus cmRNA strategies and formulation capabilities. |
| Politecnico di Torino – Valentina Cauda valentina.cauda@polito.it ETPN member* | 3D bioprinted coaxial tissue models and complex co-culture systems for drug testing, biodistribution and stimuli-responsive therapies. |
| University of Bologna – Giampaolo Zuccheri giampaolo.zuccheri@unibo.it ETPN member* | Ordered arrays of heterotypical spheroids / organoids with controllable composition, compatible with patient-derived cells. |
| CIDETEC – Diego Cortizo dcortizo@cidetec.es ETPN member* | Injectable/printable hydrogels, cell and organoid encapsulation, scale-up, pilot production and regulatory adaptation of manufacturing processes. |
| GENYO / University of Granada – Teresa Valero tvalero@go.ugr.es ETPN member* | Multiplex barcoding of nanoparticles, liquid-biopsy biomarker assays, CyTOF / Bio-Plex and strong omics support. |
| UMC Utrecht – Zhiyong Lei zlei@umcutrecht.nl ETPN member* | Engineered EVs, TOP-EV, synthetic LNPs and translational delivery expertise across several applications. |
| University of Padova – Gianfranco Pasut gianfranco.pasut@unipd.it ETPN member* | LNP preparation / targeting functionalization and antibody-drug / polymer conjugates. |
| CNR Nanoscience Institute, Pisa – Marco Cecchini marco-cecchini@cnr.it | Advanced biosensors and SAW/BAW-based lab-on-chip systems for biomarker detection in fluids. |
| UNIGE – Sara Baldassari sara.baldassari@unige.it | Biomimetic nanovesicles made from cell membranes, loading and characterization, with glioblastoma-relevant experience. |
| University of Urbino – Mattia Tiboni mattia.tiboni@uniurb.it | Personalizable 3D-printed microfluidics for liposomes, polymeric nanoparticles and hybrid systems with DoE optimization. |
4) HORIZON-HLTH-2026-01-TOOL-05 — Leveraging EU-funded collaborative research in regenerative medicine
Emerging project signal
| Lead | Project signal |
|---|---|
| University of Salerno – Giovanna Della Porta gdellaporta@unisa.it | P4FIT Next – Advancing Perspectives for Future Innovation in Tendon A credible follow-on concept leveraging the completed P4FIT Plus initiative to accelerate innovative strategies for tendon health, inflammation management and rehabilitation. Looking for: nanomedicine experts for tendon therapies, AI-assisted diagnosis, lipid nanovesicles for mRNA delivery, immunomodulation, clinical orthopaedics, tendon explants and rehabilitation expertise. |
Selected open collaboration pool around TOOL-05
| Affiliation | Offer |
|---|---|
| UMC Utrecht – Zhiyong Lei zei@umcutrecht.nl ETPN member* | Engineered EVs, TOP-EV and synthetic targeted LNPs, with track record in cardiac regeneration and in vivo CAR-T applications. |
| University of Naples Federico II – Fabiana Quaglia quaglia@unina.it ETPN member* | HTFS, microfluidic formulation, scalable RNA/nanoparticle delivery systems, GMP-oriented scale-up and tech transfer. |
| University of Padova – Gianfranco Pasut gianfranco.pasut@unipd.it ETPN member* | Targeted LNP functionalization, antibody-drug conjugates and polymer conjugates. |
| UNIMORE – Giovanni Tosi gtosi@unimore.it ETPN member* | LNP platform with GLP microfluidics for RNA delivery to stem cells ex vivo, including Cas9 delivery as RNP complex. |
| CiMUS / USC – Marcos García marcos.garcia@usc.es ETPN member* | Implantable hydrogels activated with cmRNA, already tested in advanced models for cartilage regeneration. |
| Postnova – Florian Meier florian.meier@postnova.com ETPN member* | Full physicochemical characterization toolbox for LNPs, viruses, EVs, liposomes and metallic nanoparticles. |
| University of Sheffield – Prof. Zoltan Kis group m.maamra@sheffield.ac.uk | Scalable manufacturing of RNA-LNP formulations using modelling + experiments; CEPI-backed automated manufacturing equipment development. |
| UNIGE – Sara Baldassari sara.baldassari@unige.it | Biomimetic nanovesicle production and characterization, adaptable delivery logic beyond oncology. |
| University of Urbino – Mattia Tiboni mattia.tiboni@uniurb.it | 3D-printed microfluidics for a wide range of nanomedicines with DoE-driven process optimization. |
5) HORIZON-HLTH-2026-01-TOOL-07 — Establishing a European network of Centres of Excellence (CoEs) for ATMPs
Potential network lead signal
| Lead | Signal |
|---|---|
| Foundation Gene Therapy and RNA Therapeutics – Fabiana Quaglia quaglia@unina.it rna-genetherapy.eu | A promising direction around a European network of excellence in RNA therapeutics and gene therapy, with strong formulation, scale-up and translational support logic. |
Open collaboration pool
| Affiliation | Offer |
|---|---|
| Maria José Alonso Lab – University of Santiago de Compostela mariaj.alonso@usc.es lucia.sanjurjo.bouza@sergas.es ETPN member* | Non-viral nanoassemblies for highly efficient T-cell transfection, linked to advanced therapy manufacturing centres in Spain. |
| CiMUS / USC – Marcos García marcos.garcia@usc.es ETPN member* | Can act as liaison with a strong biomedical centre combining advanced therapies, biomaterials, nanomedicine and translational biomedical research. |
| UNIMORE – Giovanni Tosi gtosi@unimore.it ETPN member* | GLP-grade nanoparticles for RNA and enzyme delivery, plus broader network/platform ambition through NANOINTEGRATE. |
| UMC Utrecht – Zhiyong Lei zlei@umcutrecht.nl ETPN member* | Engineered EVs, LNPs/liposomes, mRNA production, microfluidics, LNP manufacturing/validation and patient-derived EV engineering. |
| Postnova – Florian Meier florian.meier@postnova.com ETPN member* | Advanced characterization suite for LNPs, viruses, EVs, liposomes and metallic nanoparticles. |
| University of Porto – Nano4Med Group mcsp@fe.up.pt | Broad nano drug delivery and BBB-crossing expertise with strong characterization infrastructure. |
6) EIC Pathfinder Open 2026
Coordinator-style project signals
| Lead | Project signal |
|---|---|
| Project BONES – Valentina Cauda / Luisa De Cola valentina.cauda@polito.it luisa.decola@unimi.it ETPN member* | Bone-disease concept focused on chondrocytes, combining clinical bone expertise, EV-mimicking nanoparticles, bone-targeting chemistry and GMP nanoparticle manufacturing. Specific missing piece highlighted on the board: AI partner for prediction and design of bone-targeting peptides. |
| UMC Utrecht – Zhiyong Lei zlei@umcutrecht.nl zei@umcutrecht.nl ETPN member* | Engineered EV/AAV approach to tackle BBB limitations in brain / neurodegeneration-related diseases. Looking for: clinicians, disease models (organoids / animals) and a company for upscale production of EV/AAV. |
Open collaboration pool
| Affiliation | Offer |
|---|---|
| University of Bologna – Giampaolo Zuccheri giampaolo.zuccheri@unibo.it ETPN member* | Ordered heterotypical spheroid arrays in multiplate format, compatible with patient-derived cells and advanced “cancer-in-a-well” concepts. |
| Postnova florian.meier@postnova.com ETPN member* | High-level characterization of nanomedicines, nanoparticles, viruses and EVs for radical vector or carrier concepts. |
| University of Turin – Luigi Battaglia luigi.battaglia@unito.it | Patented PS-PIT method for ultrasmall solid lipid nanoparticles: solvent-free, low-energy, scalable, BBB-relevant and industrialisable. |
| Laura Sánchez – ophthalmic device manufacturer laurasanchez@ajlsa.com | Open to disruptive Pathfinder concepts in bioprinting, regenerative medicine, smart implants, advanced biomaterials and AI-assisted diagnostics in ophthalmology. |
| Nano4Med Group – University of Porto mcsp@fe.up.pt | BBB-crossing drug delivery, broad nanocarrier expertise, biosensors and full infrastructure. |
| Gil Gonçalves – University of Aveiro ggoncalves@ua.pt | Nanocapsules and machine-learning-supported high-throughput screening of physicochemical and biological performance. |
| CNR Nanoscience Institute, Pisa – Marco Cecchini marco-cecchini@cnr.it | Advanced biosensors, SAW/BAW devices and microfabrication capabilities relevant for disruptive monitoring concepts. |
| UNIGE – Sara Baldassari sara.baldassari@unige.it | Biomimetic nanovesicles, BBB passage assays and extensive characterization, with tumour-origin cell membrane know-how. |
| Brenta pama@brenta.net | Inorganic carrier platform for better delivery, stabilization and local activity of diverse actives. |
7) EIC Pathfinder Challenges 2026
Coordinator signal
| Lead | Project signal |
|---|---|
| Inside Therapeutics + Microfluidic Innovation Centers audrey.nsamela@insidetx.com ETPN member* | Challenge targeted: Biotechnology for Healthy Ageing Lead direction: senescence / inflammaging-focused intervention in a disease area where delivery is difficult but still realistic at Pathfinder stage. Opportunity zones highlighted by the team: transient rejuvenation or reprogramming pulses; senescence / inflammaging modulation; tissue-selective delivery in aged biology. Looking for: clinicians with real elderly patient samples and partners in senescence biology, aged OA models, translational rheumatology, organ-on-chip/NAM, vascular ageing, immunology/inflammaging, RNA engineering, muscle ageing biology and regenerative medicine. |
Additional open signal
| Affiliation | Offer |
|---|---|
| Laura Sánchez – ophthalmic device manufacturer laurasanchez@ajlsa.com | Interest in building or joining a disruptive consortium on presbyopia, with a focus on crystallin or ciliary muscle regeneration. |
Additional calls on the radar
The calls below were discussed and did generate some useful signals, but the session dynamics around them were clearly lighter than for the sections above.
HORIZON-HLTH-2026-01-DISEASE-15 — Scaling up innovation in cardiovascular health
| Affiliation | Signal |
|---|---|
| UNIMORE – Giovanni Tosi gtosi@unimore.it ETPN member* | GLP microfluidics for LNP optimization with DoE; anti-inflammatory LNPs embedded in electrospun scaffolds. |
| EVGenomics ApS – Yan Yan yan@evgenomics.com | EV-based biomarker discovery, EV-RNA sequencing and multi-omics panel construction. |
| CNR Nanoscience Institute, Pisa – Marco Cecchini marco-cecchini@cnr.it | Biomarker-monitoring biosensors in biological fluids. |
HORIZON-HLTH-2026-01-IND-03 — Regulatory science to support translational development of patient-centred health technologies
| Affiliation | Signal |
|---|---|
| Postnova – Florian Meier florian.meier@postnova.com ETPN member* | Advanced nanomedicine characterization, useful for evidence generation and translation. |
| CiMUS / IDIS / USC – José A. Costoya josea.costoya@usc.es ETPN member* | 2D/3D cancer models, GM mice and xenografts for validation of diagnostic and therapeutic tools. |
| Laura Sánchez – ophthalmic medical device manufacturer laurasanchez@ajlsa.com | Direct MDR Class III device experience from preclinical evidence generation to clinical evaluation and post-market surveillance. |
HORIZON-HLTH-2026-04-CARE-04 — Enhancing and enlarging the European Partnership on Personalised Medicine (EP PerMed)
| Affiliation | Signal |
|---|---|
| UNIMORE – Giovanni Tosi gtosi@unimore.it ETPN member* | Broad “NANOINTEGRATE” concept linking validated models, targeted nanocarriers and GMP-compliant manufacturing. |
| CNR Pisa – Ilaria Tonazzini ilaria.tonazzini@cnr.it | Brain nanodelivery for oligonucleotides, neuropathological models and polymeric nanovectors. |
| University of Turin – Luigi Battaglia luigi.battaglia@unito.it | Homologous targeting strategy for intralipid nanoemulsions wrapped with cell-membrane fragments. |
Cluster 4 radar calls
| Call / actor | Signal |
|---|---|
| MAT-PROD-25 Postnova – Florian Meier florian.meier@postnova.com ETPN member* | Characterization support for complex nanosystems, including materials relevant to sensing / healthtech. |
| MAT-PROD-25 CNR Nanoscience Institute, Pisa – Marco Cecchini marco-cecchini@cnr.it | Advanced biosensors and micro/nanofabrication relevant to sensing-enabled advanced materials. |
IHI Call 12
Several technology offers appeared, but no visible mature consortium backbone with a credible private-side / contributing partner path emerged on the board.
| Affiliation | Signal |
|---|---|
| UMC Utrecht – Zhiyong Lei zlei@umcutrecht.nl ETPN member* | EVs, LNPs, mRNA production, microfluidics and brain-disease delivery angle. |
| University of Padova – Gianfranco Pasut gianfranco.pasut@unipd.it ETPN member* | LNP targeting and conjugation expertise. |
| University of Turin – Luigi Battaglia luigi.battaglia@unito.it | Industrializable ultrasmall SLN platform with BBB potential. |
Mission Cancer 2026 — HORIZON-MISS-2026-02-CANCER-03
| Affiliation | Signal |
|---|---|
| University of Bologna – Giampaolo Zuccheri giampaolo.zuccheri@unibo.it ETPN member* | Patient-compatible cancer-in-a-well systems using ordered spheroid arrays. |
| University of Granada / GENYO – Teresa Valero tvalero@go.ugr.es ETPN member* | Customized multiplex biomarker assays for proteins, DNA and RNA. |
| University of Pavia mariacristina.bonferoni@unipv.it ETPN member* | Sensitizer-loaded nanoformulations for photodynamic therapy. |
EIC Transition 2026
Next applications cut-off: 16 September 2026
Official EIC Transition page
The call was mentioned during the brokerage, but no public participant input was captured on the board. We therefore keep it on the radar without publishing a contact pool here.
Important disclaimer
This directory is provided by the European Technology Platform on Nanomedicine (ETPN) to facilitate partnership building. It does not constitute any endorsement by the European Commission. By using the contact details above, please respect GDPR principles and each expert’s own confidentiality expectations.
How to make this page useful for you
The ETPN acts as a true connector: it helps translate strong but fragmented expertise into real proposal-building momentum. This page is meant to make that momentum easier to use for participants, for coordinators, and for the wider healthtech ecosystem.
If you find a relevant profile here, write a short, specific e-mail, cite the call code, and explain very clearly what kind of gap or contribution you have in mind. If you need help orienting yourself in this landscape, contact the ETPN Secretariat:
secretariat@etp-nanomedicine.eu.
Pro tip: the strongest sections of this Spring 2026 edition were TOOL-03, TOOL-05, DISEASE-03, DISEASE-04 and EIC Pathfinder. That is where the richest signals and the most actionable partner pools appeared.
Stay in the fast lane: become an ETPN member!
From 2026 onward, some of these brokerage follow-up resources will become more member focused. If this page is useful to you, that is also because many ETPN members keep bringing real translational, industrial, regulatory and clinical value into the room.